Recent Developments in the Third Generation Inhibitors of Bcr-Abl for Overriding T315I Mutation

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|18|14|2146-2157

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.18, Iss.14, 2011-05, pp. : 2146-2157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of ABL and the ABL-T315I Mutation

By  

Current Topics in Medicinal Chemistry, Vol. 8, Iss. 10, 2008-07 ,pp. : 905-921

Bentham Science Publishers

Access to resources Recommend Favorite

New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms

By  

Current Medicinal Chemistry, Vol. 17, Iss. 13, 2010-05 ,pp. : 1220-1245

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity

By  

Current Medicinal Chemistry, Vol. 18, Iss. 34, 2011-12 ,pp. : 5174-5184

Bentham Science Publishers

Access to resources Recommend Favorite

New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells

By Santucci Maria   Mancini Manuela   Corradi Valentina   lacobucci Ilaria   Martinelli Giovanni   Botta Maurizio   Schenone Silvia  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 876-878

Springer Publishing Company

Access to resources Recommend Favorite

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

By Doggrell Sheila A   Christensen Anne-Marie  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 1, 2011-01 ,pp. : 157-163

Informa Healthcare

Access to resources Recommend Favorite